Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Blog: Affordable Care Act

    April 1, 2015 | Affordable Care Act, USA 

    What does the future hold for the US pharma industry?

    Everywhere you go in the States, you hear talk of the Affordable Care Act, also known as ObamaCare.  In essence, the ACA is designed to broaden coverage to the millions of Americans who have not had healthcare in the past due to not being employed or just not being able to afford it.  ACA had a rocky time getting passed into law and now that it has launched on January 1, 2014, things are not getting much  easier.  After the President promised that no one who likes his/her doctor would have to switch doctors,  some folks are being dropped by their insurance and do have to leave their doctors.  Younger people almost certainly have to pay more than they have been paying for coverage because the way the new system is structured,  younger, healthier people are underwriting the costs for older people who utilize the healthcare system more frequently (and at greater cost). At the core of the debate is a values questions:  some people truly believe that everyone should have access to the healthcare system as provided by the ACA. Others exude a really American spirit of not wanting any government intervention or interference in their lives. So despite the fact that this program might be advantageous to many, it represents an intrusion. This disagreement is unlikely to be easily resolved as it is a core values question. 

    It has been almost a given that full time employees offer some level of healthcare coverage to employees and some employers are taking advantage of this shift in the landscape to divorce employment from healthcare benefits and force  their employees to shop independently for coverage on the newly created exchanges.  In fact,  this has happened to my own husband.  So this represents added expense to the employees, unless the employers decide to underwrite the cost in some way (which has yet to be determined).  This is “a great unknown” and something that will be determined company to company, not on a national level.

    There are some facts that are emerging, although the system is still unfolding.  Some folks will have to change physicians and physicians will have to see more patients, possibly at a lower reimbursement rate than before.  The rates themselves are still unclear and may not be clear for quite some time.  The system is structured so that everyone will have access to care; in fact, everyone must have access to care. That means that there are financial penalties if people don’t sign up. 

    So everyone is a bit at sea.  Pharma companies, too are wondering about the impact of the ACA on their worlds.  What guidelines will physicians have to follow in prescribing?  What tests will be covered?   What types of reporting will they have do (electronic record keeping)?  I spoke to my colleague from our sister company,  Access Partnership about this.  His idea is that   things are unclear in part because, although the Supreme Court upheld the centerpiece of the Affordable Care Act more than a year ago, there are still several legal challenges to the new system, which may slow down the implementation and make it difficult to envision how the new system will play out over time. 

    As of right now, the Affordable Care Act is just beginning and it is difficult to see “around the next bend” as to what the long term implications will be for the interested parties (and by that I mean everyone!).

    Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1Pj6vu1

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Webcast: AI in MRX: Harnessing the power of AI + people

    Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...

    Navigating challenges of MedTech research with rare-disease patients

    Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.

    Product launch: What market research when?

    Get the insights you need, when you need them, for your product launch planning

    Therapy Watch launches new tracker covering Alzheimer’s Disease

    The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

    Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

    Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

    Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

    Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

    Therapy Watch launches new tracker covering Postpartum Depression

    The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

    Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market

    Authored by: Marc Garcia and Tania Rodrigues

    Infographic: Rare Diseases in China

    How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

    New syndicated COPD report now available

    Living with COPD 2023